Cellebrite DI Ltd. (NASDAQ:CLBT) Receives Consensus Rating of “Buy” from Brokerages

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have been given an average rating of “Buy” by the eight analysts that are currently covering the firm, MarketBeat.com reports. Eight analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $21.57.

Several research analysts have issued reports on CLBT shares. Craig Hallum raised their target price on Cellebrite DI from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Needham & Company LLC increased their price objective on shares of Cellebrite DI from $21.00 to $28.00 and gave the stock a “buy” rating in a research note on Wednesday, January 22nd. Finally, JPMorgan Chase & Co. boosted their target price on shares of Cellebrite DI from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Monday, December 16th.

Institutional Investors Weigh In On Cellebrite DI

A number of institutional investors have recently bought and sold shares of CLBT. Juncture Wealth Strategies LLC boosted its stake in shares of Cellebrite DI by 0.8% in the fourth quarter. Juncture Wealth Strategies LLC now owns 60,003 shares of the company’s stock worth $1,322,000 after acquiring an additional 505 shares during the period. Strategic Advisors LLC lifted its holdings in Cellebrite DI by 3.4% in the 4th quarter. Strategic Advisors LLC now owns 29,082 shares of the company’s stock worth $641,000 after purchasing an additional 950 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. boosted its stake in Cellebrite DI by 59.6% in the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company’s stock worth $33,000 after purchasing an additional 1,017 shares during the period. Tower View Wealth Management LLC grew its holdings in Cellebrite DI by 1.2% during the 3rd quarter. Tower View Wealth Management LLC now owns 130,647 shares of the company’s stock valued at $2,200,000 after buying an additional 1,500 shares in the last quarter. Finally, Quarry LP bought a new stake in shares of Cellebrite DI during the third quarter valued at approximately $27,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Trading Up 2.1 %

Shares of CLBT stock opened at $26.00 on Friday. Cellebrite DI has a 12-month low of $8.91 and a 12-month high of $26.04. The stock has a market capitalization of $5.35 billion, a P/E ratio of -16.77, a P/E/G ratio of 3.55 and a beta of 1.47. The firm’s 50 day moving average is $21.98 and its 200 day moving average is $18.63.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. The firm had revenue of $106.90 million for the quarter, compared to the consensus estimate of $102.06 million. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. The company’s revenue for the quarter was up 27.0% on a year-over-year basis. During the same period last year, the business posted $0.09 EPS. As a group, equities analysts predict that Cellebrite DI will post 0.32 earnings per share for the current year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.